Skip to main content

Dr. Arthur Kavanaugh: Biosimilars and Drug Switching (Abstract 19L)

Jan 30, 2017 1:54 pm
Dr. Arthur Kavanaugh discusses abstract 19L: Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway, as presented at the 2016 ACR/ARHP Annual Meeting (…).

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.